High Flow Nasal Cannula in Preventing Reintubation in Extubated Patients with Treated Type I Respiratory Failure
/ 0
- Details
- Category: Vol. 93, March 2025
- Hits: 20
High Flow Nasal Cannula in Preventing Reintubation in Extubated Patients with Treated Type I Respiratory Failure, MOHAMED SIDKY M. ZAKI, SAHAR M. TALAAT, AMR F. HAFEZ and MUSTAFA M. MABROUK IBRAHIM
Abstract
Background: Respiratory failure (RF) is a syndrome caused by a multitude of pathological states; therefore, the ep idemiology of this disease process is difficult to ascertain. In 2017, in the United States of America, however, the incidence of respiratory failure was found to be 1,275 cases per 100,000 adults. The case definition used in this study included all diag nosis codes that included respiratory failure as a component. The epidemiology of respiratory failure is dependent mainly on the cause leading to the failure. Below, some common causes of respiratory failure and the relevant trends are listed. Aim of Study: Evaluation of the efficacy of high flow nasal cannula (HFNC) in reducing the risk of reintubation following extubation of patients with treated type I respiratory failure. Subjects and Methods: This study was a prospective study conducted on 128 extubated patients with type I respiratory failure to compare the results from using HFNC versus Con ventional oxygen mask. The study period from February 2024 to Augusts 2024. Results: The HR for the HFNC group compared to the con ventional therapy group is 0.26 (95% CI: 0.12, 0.60), with a significant difference between the two groups (p=0.002). Our results suggested that patients in the HFNC group had a sub stantial benefit of increasing the time to reintubation compared to patients in the conventional therapy group. Conclusion: Our study findings contribute valuable in sights into the ongoing evaluation of HFNC therapy. While HFNC did not demonstrate significant advantages in terms of weaning time or ICU length of stay, it did show a noteworthy benefit of increasing time to reintubation. Future studies should aim to explore these variables and refine HFNC protocols to optimize patient outcomes across diverse clinical settings.